H. pylori: Should You Get Tested and Treated? A Look at Testing Methods and the Link to Gastric Cancer
Helicobacter pylori (H. pylori) is a bacterium that colonizes the stomach. It is a major cause of chronic gastritis and peptic ulcers (gastric and duodenal ulcers) and is classified as a Group 1 (definite) carcinogen by the WHO IARC—most gastric cancers are linked to it. However, most infected individuals are asymptomatic, and not everyone requires testing or treatment. Common tests include the urea breath test, stool antigen test, and endoscopic biopsy. Blood antibody tests only indicate past exposure and cannot confirm current infection or successful eradication. Studies show that eradication reduces (but does not eliminate) gastric cancer risk; a large-scale eradication program in Matsu, Taiwan, is a notable example. Decisions on testing and treatment should be made by a physician based on symptoms and risk assessment, following the latest guidelines from the Taiwan Health Promotion Administration. Eradication therapy requires a prescription; do not self-medicate. This page provides neutral information, not medical advice.
What is H. pylori? Its relationship with gastric cancer and peptic ulcers
It is a bacterium that survives in the acidic stomach and may cause disease through chronic inflammation:
- It is a major cause of chronic gastritis and peptic ulcers (gastric and duodenal ulcers).
- The WHO IARC classified it as a Group 1 (definite) carcinogen in 1994; it is a major risk factor for gastric adenocarcinoma and gastric MALT lymphoma—most gastric cancers are linked to infection.
- Key point: Most infected individuals are asymptomatic; infection does not mean cancer will develop, but it is a modifiable risk factor.
How common is it in Taiwan? How is it transmitted?
H. pylori is common worldwide, including in Taiwan:
- Infection usually occurs in childhood, primarily via fecal-oral or oral-oral routes (e.g., shared utensils, poor hygiene, household clustering).
- Prevalence in Taiwanese adults is around 30%, with higher rates in some high-risk areas (e.g., certain indigenous communities)—figures vary by source and year; refer to the latest data from the Health Promotion Administration.
- Most infected individuals are asymptomatic, so infection status often requires testing.
How is it tested? Differences and precautions for each method
Tests are divided into non-invasive and invasive types, with different accuracy and uses:
- Urea breath test (carbon-13/carbon-14): Detects active infection with high accuracy; also commonly used for post-treatment confirmation. Stool antigen test also has high sensitivity.
- Blood antibody test: Only indicates past exposure; may remain positive after eradication; not suitable for confirming current infection or cure.
- Endoscopic biopsy (invasive): Allows rapid urease test, histology, and culture (culture can detect antibiotic resistance).
- Note: Recent use of proton pump inhibitors (PPIs), antibiotics, or bismuth can cause false negatives in breath/stool tests; these medications should be stopped as directed (PPIs for about 2 weeks, antibiotics or bismuth for about 4 weeks) before testing.
Eradication therapy and gastric cancer risk
Eradication refers to the use of medication to clear the bacterium, a medical procedure prescribed by a physician:
- Standard is combination therapy: a PPI plus two or more antibiotics (triple therapy or bismuth-containing quadruple therapy) for about 10–14 days.
- Antibiotic resistance (especially to clarithromycin) is a growing concern affecting success rates; therefore, the regimen must be determined by a physician based on individual conditions and local resistance patterns. Do not self-medicate.
- Post-treatment confirmation should be done about 4 weeks after completing therapy (and after stopping PPIs for about 2 weeks) using a breath or stool antigen test (not blood antibody).
- Evidence shows that eradication reduces gastric cancer risk (with greater benefit in high-risk groups). In Matsu, Taiwan, a large-scale eradication program reduced prevalence from about 64% to about 15% and gastric cancer incidence by about 50% (Gut, 2021). However, eradication reduces rather than eliminates risk.
Who should be tested? Neutral recommendations
Decisions on testing and treatment should be made by a physician based on symptoms and risk assessment:
- Generally, testing is recommended for those with current or past peptic ulcers, gastric MALT lymphoma, after endoscopic resection of early gastric cancer, or with a family history of gastric cancer (first-degree relative) or residence in high-risk areas.
- Universal screening for asymptomatic, average-risk individuals is context-dependent and policy is still evolving—discuss with your physician and refer to the latest gastric cancer prevention guidelines from the Health Promotion Administration (currently targeting high-risk groups in Taiwan).
- Reinfection rates after successful eradication in adults are generally low. However, this is a medical decision; antibiotic misuse can worsen resistance. Do not self-medicate. This page provides neutral information, not medical advice.
FAQ
Does H. pylori definitely cause gastric cancer?
Not necessarily. It is classified as a Group 1 carcinogen by the WHO IARC and is a major risk factor for gastric cancer—most gastric cancers are linked to it. However, most infected individuals remain asymptomatic for a long time, and infection does not mean cancer will develop. It is a "modifiable risk factor." Whether testing and treatment are needed should be determined by a physician based on symptoms and risk assessment. This page provides neutral information, not medical advice.
How is H. pylori tested? Which test is accurate?
Common non-invasive tests include the urea breath test (carbon-13/carbon-14) and stool antigen test, which detect active infection with high accuracy. The breath test is also often used for post-treatment confirmation. Blood antibody tests only indicate past exposure and cannot confirm current infection or cure. Endoscopic biopsy is invasive but allows for histology and culture (including antibiotic susceptibility testing). Recent use of PPIs, antibiotics, or bismuth can cause false negatives; these medications should be stopped as directed before testing.
Is H. pylori contagious? How is it transmitted?
Yes. Infection usually occurs in childhood, primarily through fecal-oral or oral-oral routes, associated with shared eating utensils, poor hygiene, and household clustering. Therefore, family members often carry the bacterium together. The prevalence in Taiwanese adults is around 30%, with higher rates in some high-risk areas (based on the latest data from the Health Promotion Administration). Most people are asymptomatic and may only know their status through testing.
How is H. pylori eradicated? Can it recur after eradication?
Eradication involves a prescription combination therapy: a PPI plus two or more antibiotics (triple therapy or bismuth-containing quadruple therapy) for about 10–14 days. Due to rising antibiotic resistance, the regimen must be determined by a physician; do not self-medicate. About 4 weeks after completing therapy (and after stopping PPIs for about 2 weeks), a breath or stool antigen test should be done to confirm eradication. Reinfection rates in adults after successful eradication are generally low.
If H. pylori is eradicated, will I not get gastric cancer?
Not exactly. Evidence shows that eradication reduces gastric cancer risk, with greater benefit in high-risk groups. For example, a large-scale eradication program in Matsu, Taiwan, reduced gastric cancer incidence by about 50% (Gut, 2021). However, it reduces rather than eliminates risk; other factors and regular follow-up remain important. Discuss eradication and follow-up with your physician.
If I have no symptoms, should I get tested for H. pylori?
It depends on individual risk. Testing is generally recommended for those with current or past peptic ulcers, gastric MALT lymphoma, after endoscopic resection of early gastric cancer, or with a family history of gastric cancer (first-degree relative) or residence in high-risk areas. For asymptomatic individuals at average risk, universal screening is still under policy development. Discuss with your physician and refer to the latest gastric cancer prevention guidelines from the Health Promotion Administration (currently targeting high-risk groups in Taiwan).
This page is a neutral compilation of information for reference only, not Medical advice, and does not constitute any diagnostic commitment.